Lixte Biotechnology Correlations
| LIXT Stock | USD 1.30 0.10 7.14% |
The current 90-days correlation between Lixte Biotechnology and Allarity Therapeutics is -0.04 (i.e., Good diversification). The correlation of Lixte Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Lixte Biotechnology Correlation With Market
Very good diversification
The correlation between Lixte Biotechnology Holdings and DJI is -0.22 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Lixte Biotechnology Holdings and DJI in the same portfolio, assuming nothing else is changed.
Lixte |
Moving together with Lixte Stock
Moving against Lixte Stock
| 0.32 | KURA | Kura Oncology | PairCorr |
| 0.6 | CRSP | Crispr Therapeutics | PairCorr |
| 0.48 | ANAB | AnaptysBio | PairCorr |
| 0.68 | KO | Coca Cola | PairCorr |
| 0.62 | MCD | McDonalds | PairCorr |
| 0.51 | WPM | Wheaton Precious Metals | PairCorr |
| 0.48 | T | ATT Inc Aggressive Push | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Lixte Stock performing well and Lixte Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lixte Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ALLR | 4.81 | (0.29) | 0.00 | 0.39 | 0.00 | 9.86 | 47.01 | |||
| NRBO | 4.27 | (0.63) | 0.00 | (44.27) | 0.00 | 11.73 | 24.54 | |||
| HILS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| VRAX | 6.05 | 0.08 | 0.02 | (0.06) | 6.57 | 16.67 | 59.66 | |||
| QNRX | 6.33 | (0.83) | 0.00 | 0.54 | 0.00 | 16.07 | 58.63 | |||
| INDP | 3.46 | (0.21) | 0.00 | (0.79) | 0.00 | 6.33 | 20.25 | |||
| KTTA | 4.76 | (1.29) | 0.00 | (1.48) | 0.00 | 8.06 | 53.63 | |||
| KRBP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BDRX | 4.12 | (0.71) | 0.00 | (0.68) | 0.00 | 9.56 | 43.72 | |||
| PMVP | 1.75 | (0.32) | 0.00 | (0.62) | 0.00 | 4.38 | 9.70 |
Lixte Biotechnology Corporate Management
| Johannes MD | Chief Officer | Profile | |
| James MD | Chief Officer | Profile | |
| Robert Weingarten | VP CFO | Profile | |
| Eric JD | VP COO | Profile | |
| John MD | President, Founder | Profile |